<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02228213</url>
  </required_header>
  <id_info>
    <org_study_id>MIS416-202</org_study_id>
    <secondary_id>U1111-1166-0910</secondary_id>
    <nct_id>NCT02228213</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple Sclerosis</brief_title>
  <official_title>A Phase 2B Randomised, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of MIS416 in the Treatment of Subjects With Secondary Progressive Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innate Immunotherapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Syneos Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Innate Immunotherapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether MIS416 administered once weekly over 12&#xD;
      months is safe, tolerable, and improves a range of signs and symptoms associated with&#xD;
      secondary progressive multiple sclerosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objectives of the study are to:&#xD;
&#xD;
        1. Determine the efficacy of MIS416, relative to placebo, when administered repeatedly via&#xD;
           weekly intravenous (IV) administration to subjects with Secondary Progressive Multiple&#xD;
           Sclerosis, as assessed by its effect on measures of neuromuscular function.&#xD;
&#xD;
        2. Determine the safety and tolerability of a weekly regimen of MIS416.&#xD;
&#xD;
      The secondary objectives of the study are to:&#xD;
&#xD;
        1. Determine the effect of MIS416 on disease activity and neurodegeneration by assessing&#xD;
           changes in Magnetic Resonance Imaging (MRI) markers including lesions, whole brain&#xD;
           atrophy (WBA) and Magnetization Transfer Ratio (MTR).&#xD;
&#xD;
        2. Determine the effect of MIS416 on Patient Reported Outcomes (PRO) related to disability&#xD;
           and health status.&#xD;
&#xD;
        3. Assess, in a subset of subjects, the pharmacodynamic (PD) effects of MIS416, including&#xD;
           effects on serum, Peripheral Blood Mononuclear Cell (PBMC), and Cerebral Spinal Fluid&#xD;
           (CSF) cytokine/chemokine levels and expression patterns.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">June 2017</completion_date>
  <primary_completion_date type="Actual">May 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline of neuromuscular function at 12 months</measure>
    <time_frame>Baseline, 3, 6, 9 and 12 months</time_frame>
    <description>Neuromuscular function will be assessed using the following test:&#xD;
MS Function Composite (MSFC), comprising the; timed 25 Foot Walk, 9 Hole Peg Test (9HPT), and Paced Auditory Serial Addition Test (PASAT);&#xD;
Jebsen Hand Function Test (JHFT);&#xD;
Grip, tip and key pinch strength;&#xD;
Symbol digit modalities test (SDMT);&#xD;
Sloan low-contrast letter visual acuity (SLCVA);&#xD;
6-minute walk test (6MWT);</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of Participants with Serious and Non-Serious Adverse Events</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Safety assessments will be conducted at each study visit and include; characterization of the type, incidence, severity, timing, seriousness, and relationship to treatment of adverse events (AEs); effects on vital signs and clinical laboratory parameters; changes on electrocardiograms (ECGs); and at 3 months and 12 months - the number of gadolinium-enhancing lesions on cranial MRI assessments.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of disability and health status at 12 months</measure>
    <time_frame>Baseline, 3, 6, 9, and 12 months</time_frame>
    <description>Disability and health status will be assessed using the following assessments and patient reported outcomes:&#xD;
Expanded Disability Status Scale (EDSS)&#xD;
Patient Reported Outcomes (PROs) including;&#xD;
SF-36 and its components;&#xD;
MS Impact Scale (MSIS-29);&#xD;
Neurological Fatigue Index for MS (NFI-MS);&#xD;
Brief Pain Inventory (BPI).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of neurodegeneration by assessing changes in Magnetic Resonance Imaging (MRI) markers at 12 months</measure>
    <time_frame>Baseline, 3, and 12 months</time_frame>
    <description>Disease activity and neurodegeneration will be assessing using Magnetic Resonance Imaging (MRI) markers including lesions, whole brain atrophy (WBA) and Magnetization Transfer Ratio (MTR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of activity of immune biomarkers in serum</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>The effect on immune biomarkers will include the analysis of serum for some or all of the following markers: IP-10 (CXCL10), MCP-1 (CCL2), MIG (CXCL9), IL-8 (CXCL8), IFNγ, Neopterin, IL-1RA, sTNF-R, IL-12/23, p40, CD62E (E-selectin), CD54 (ICAM-1), and CD106 (VCAM-1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of activity of immune biomarkers in cerebrospinal fluid (CSF)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>The effect on immune biomarkers will include the analysis of CSF for some or all of the following markers: IP-10 (CXCL10), MCP-1 (CCL2), MIG (CXCL9), IL-8 (CXCL8), IFNγ, Neopterin, IL-1RA, sTNF-R, IL-12/23, p40, CD62E (E-selectin), CD54 (ICAM-1), and CD106 (VCAM-1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Peripheral Blood Mononuclear Cell (PBMC) immune biomarkers</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Some or all of these biomarkers may be assayed ex vivo: PBMC expression of mRNA encoding proteins involved in myeloid differentiation and immune regulatory function (e.g. VEGF, Arginine, INOS, IL-10, MMP9); PBMC myeloid subset production of IL-10, TGFβ, IL-6, TNFα, IL-1β, IFNγ, IL-17, and GM-CSF in response to stimulation with LPS, LPS/IFNγ or MIS416 ex vivo; and PBMC subset analysis of myeloid and dendritic cell subsets for immunoregulatory cell subset markers.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">93</enrollment>
  <condition>Secondary Progressive Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>500 mcg MIS416 500 at 0.2 mg/mL administered i.v. once weekly for 52 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline administered i.v. once weekly for 52 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MIS416</intervention_name>
    <description>Intravenous administration weekly for 52 weeks</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Intravenous administration weekly for 52 weeks</description>
    <arm_group_label>Saline</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. A historical or current cranial MRI scan demonstrating T2-hyperintense lesions&#xD;
             consistent with MS.&#xD;
&#xD;
          2. Has SPMS as determined by the 2010 Update to the McDonald Criteria&#xD;
&#xD;
          3. An Expanded Disability Status Scale (EDSS) of 3.0 to 6.5 at Screening.&#xD;
&#xD;
          4. Has SPMS which, in the judgment of the investigator, has been clinically active and&#xD;
             functionally progressive within the 2 years prior to Screening&#xD;
&#xD;
          5. The absence of MS relapse for at least two years prior to Baseline.&#xD;
&#xD;
          6. Neurologically stable for at least four weeks prior to Screening.&#xD;
&#xD;
          7. Has the following laboratory values within three days prior to initiation of&#xD;
             Investigational Product:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) &gt;= 1 x 109/L;&#xD;
&#xD;
               -  Platelet count &gt;= 100 x 109/L;&#xD;
&#xD;
               -  Serum creatinine =&lt; 1.5 mg/dL;&#xD;
&#xD;
               -  Aspartate aminotransferase (AST) =&lt;2 × upper limit of normal;&#xD;
&#xD;
               -  Alanine aminotransferase (ALT) =&lt; 2 × upper limit of normal.&#xD;
&#xD;
          8. Provided written informed consent to participate.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Has primary Progressive MS (PPMS), Relapsing Remitting (RRMS), or progressive&#xD;
             relapsing MS as determined by the 2010 update to the McDonald Criteria.&#xD;
&#xD;
          2. Has not completed the discontinuation period for approved and/or investigational&#xD;
             multiple sclerosis disease modifying therapies prior to screening.&#xD;
&#xD;
          3. Has had any other immunomodulatory drug therapy or immunosuppressive therapy within&#xD;
             four weeks prior to Screening, or systemic corticosteroids within the eight weeks&#xD;
             prior to Screening.&#xD;
&#xD;
          4. Any previous exposure to investigational MS therapeutic vaccines.&#xD;
&#xD;
          5. Any use of cell-depleting monoclonal antibodies including, but not limited to,&#xD;
             Rituximab, or Ocrelizumab.&#xD;
&#xD;
          6. A diagnosis or history of collagen vascular disease (including Sjögren's syndrome and&#xD;
             systemic lupus erythematosus), anticardiolipin antibody syndrome, cerebral autosomal&#xD;
             dominant arteriopathy with subcortical infarcts and leukoencephalopathy, sarcoidosis,&#xD;
             vasculitis, Behcet's syndrome and/or Lyme disease.&#xD;
&#xD;
          7. Contraindication to MRI (e.g., pacemaker or other contraindicated implanted metal&#xD;
             device, allergy to gadolinium, or unmanageable claustrophobia).&#xD;
&#xD;
          8. A history of alcohol or drug abuse (including cannabinoid use) within two years prior&#xD;
             to Screening.&#xD;
&#xD;
          9. Has had major surgery or radiation therapy within four weeks prior to Screening.&#xD;
&#xD;
         10. Has an active infection requiring antibiotics within two weeks prior to Screening.&#xD;
&#xD;
         11. Has had active malignancy within two years of Screening, with the exception of basal&#xD;
             cell carcinoma and squamous cell carcinoma of the skin.&#xD;
&#xD;
         12. Uncontrolled congestive heart failure, myocardial infarction, cerebrovascular&#xD;
             accident, coronary/peripheral artery bypass graft surgery, or transient ischemic&#xD;
             attack within twelve weeks prior to Screening.&#xD;
&#xD;
         13. Has angina, other symptomatic coronary artery disease, or known cardiomyopathy.&#xD;
&#xD;
         14. Has symptomatic cardiac dysrhythmias requiring treatment, or persistent prolongation&#xD;
             of the QTcF (Fredericia) interval to &gt; 450 msec for males or &gt; 470 msec for females.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Silverman</last_name>
    <role>Study Director</role>
    <affiliation>Innate Immunotherapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Wesley-St. Andrew's Research Institute</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4066</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PARC Clinical Research</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nucleus Network - Centre for Clinical Studies</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Australian Neuroscience Research Institute</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurodegenerative Disorders Research</name>
      <address>
        <city>West Perth</city>
        <state>Western Australia</state>
        <zip>6005</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Optimal Clinical Trials</name>
      <address>
        <city>Auckland</city>
        <zip>1010</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P3 Research</name>
      <address>
        <city>Wellington</city>
        <zip>6021</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>August 21, 2014</study_first_submitted>
  <study_first_submitted_qc>August 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 28, 2014</study_first_posted>
  <last_update_submitted>July 12, 2017</last_update_submitted>
  <last_update_submitted_qc>July 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>multiple sclerosis</keyword>
  <keyword>SPMS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Chronic Progressive</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02228213
org study id: MIS416-202
secondary id: U1111-1166-0910
nct id: NCT02228213
lead sponsor: 
collaborator: 
has dmc: Yes
The purpose of this study is to determine whether MIS416 administered once weekly over 12
      months is safe, tolerable, and improves a range of signs and symptoms associated with
      secondary progressive multiple sclerosis.
The primary objectives of the study are to:

        1. Determine the efficacy of MIS416, relative to placebo, when administered repeatedly via
           weekly intravenous (IV) administration to subjects with Secondary Progressive Multiple
           Sclerosis, as assessed by its effect on measures of neuromuscular function.

        2. Determine the safety and tolerability of a weekly regimen of MIS416.

      The secondary objectives of the study are to:

        1. Determine the effect of MIS416 on disease activity and neurodegeneration by assessing
           changes in Magnetic Resonance Imaging (MRI) markers including lesions, whole brain
           atrophy (WBA) and Magnetization Transfer Ratio (MTR).

        2. Determine the effect of MIS416 on Patient Reported Outcomes (PRO) related to disability
           and health status.

        3. Assess, in a subset of subjects, the pharmacodynamic (PD) effects of MIS416, including
           effects on serum, Peripheral Blood Mononuclear Cell (PBMC), and Cerebral Spinal Fluid
           (CSF) cytokine/chemokine levels and expression patterns.
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Treatment
masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
measure: Change from baseline of neuromuscular function at 12 months
time frame: Baseline, 3, 6, 9 and 12 months
description: Neuromuscular function will be assessed using the following test:
MS Function Composite (MSFC), comprising the; timed 25 Foot Walk, 9 Hole Peg Test (9HPT), and Paced Auditory Serial Addition Test (PASAT);
Jebsen Hand Function Test (JHFT);
Grip, tip and key pinch strength;
Symbol digit modalities test (SDMT);
Sloan low-contrast letter visual acuity (SLCVA);
6-minute walk test (6MWT);
measure: Proportion of Participants with Serious and Non-Serious Adverse Events
time frame: Up to 12 months
description: Safety assessments will be conducted at each study visit and include; characterization of the type, incidence, severity, timing, seriousness, and relationship to treatment of adverse events (AEs); effects on vital signs and clinical laboratory parameters; changes on electrocardiograms (ECGs); and at 3 months and 12 months - the number of gadolinium-enhancing lesions on cranial MRI assessments.
measure: Change from baseline of disability and health status at 12 months
time frame: Baseline, 3, 6, 9, and 12 months
description: Disability and health status will be assessed using the following assessments and patient reported outcomes:
Expanded Disability Status Scale (EDSS)
Patient Reported Outcomes (PROs) including;
SF-36 and its components;
MS Impact Scale (MSIS-29);
Neurological Fatigue Index for MS (NFI-MS);
Brief Pain Inventory (BPI).
measure: Change from baseline of neurodegeneration by assessing changes in Magnetic Resonance Imaging (MRI) markers at 12 months
time frame: Baseline, 3, and 12 months
description: Disease activity and neurodegeneration will be assessing using Magnetic Resonance Imaging (MRI) markers including lesions, whole brain atrophy (WBA) and Magnetization Transfer Ratio (MTR).
measure: Change from baseline of activity of immune biomarkers in serum
time frame: Up to 1 year
description: The effect on immune biomarkers will include the analysis of serum for some or all of the following markers: IP-10 (CXCL10), MCP-1 (CCL2), MIG (CXCL9), IL-8 (CXCL8), IFNγ, Neopterin, IL-1RA, sTNF-R, IL-12/23, p40, CD62E (E-selectin), CD54 (ICAM-1), and CD106 (VCAM-1).
measure: Change from baseline of activity of immune biomarkers in cerebrospinal fluid (CSF)
time frame: Up to 12 months
description: The effect on immune biomarkers will include the analysis of CSF for some or all of the following markers: IP-10 (CXCL10), MCP-1 (CCL2), MIG (CXCL9), IL-8 (CXCL8), IFNγ, Neopterin, IL-1RA, sTNF-R, IL-12/23, p40, CD62E (E-selectin), CD54 (ICAM-1), and CD106 (VCAM-1).
measure: Change from baseline in Peripheral Blood Mononuclear Cell (PBMC) immune biomarkers
time frame: Up to 12 months
description: Some or all of these biomarkers may be assayed ex vivo: PBMC expression of mRNA encoding proteins involved in myeloid differentiation and immune regulatory function (e.g. VEGF, Arginine, INOS, IL-10, MMP9); PBMC myeloid subset production of IL-10, TGFβ, IL-6, TNFα, IL-1β, IFNγ, IL-17, and GM-CSF in response to stimulation with LPS, LPS/IFNγ or MIS416 ex vivo; and PBMC subset analysis of myeloid and dendritic cell subsets for immunoregulatory cell subset markers.
arm group label: Treatment
arm group type: Experimental
description: 500 mcg MIS416 500 at 0.2 mg/mL administered i.v. once weekly for 52 weeks
arm group label: Saline
arm group type: Placebo Comparator
description: Saline administered i.v. once weekly for 52 weeks
intervention type: Biological
intervention name: MIS416
description: Intravenous administration weekly for 52 weeks
arm group label: Treatment
intervention type: Drug
intervention name: Saline
description: Intravenous administration weekly for 52 weeks
arm group label: Saline
other name: Placebo
criteria: 
gender: All
minimum age: 18 Years
maximum age: 70 Years
healthy volunteers: No
last name: Michael Silverman
role: Study Director
affiliation: Innate Immunotherapeutics
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
country: Australia
country: New Zealand
responsible party type: Sponsor
mesh term: Neoplasm Metastasis
mesh term: Multiple Sclerosis
mesh term: Multiple Sclerosis, Chronic Progressive
mesh term: Sclerosis